- Correlation of HBV DNA Level and Viral Breakthrough During Lamivudine Therapy for Chronic Hepatitis B
-
Park HS, Lee DH, Heo J, Kim GH, Kang DH, Song GA, Cho M
- KMID: 760644
- Korean J Hepatol.
- 2006 Jun;12(2):173-183.
BACKGROUND/AIMS: Lamivudine is an effective therapy in chronic hepatitis B patients, but the emergence of resistant hepatitis B virus (HBV) mutants is a major concern. This study was performed... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Clinical Outcome Between Patients Continuing and Discontinuing Lamivudine Therapy in Acute Exacerbation After Viral breakthrough During Lamivudine Therapy in Chronic Hepatitis B
-
Eun JR
- KMID: 760645
- Korean J Hepatol.
- 2006 Jun;12(2):184-190.
BACKGROUNDS/AIMS: Continuation of lamivudine therapy is controversial for patients with chronic hepatitis B when viral breakthrough occurs. Moreover, the effect of continuous lamivudine therapy is unknown in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Seroepidemiology of HBV infection in South Korea, 1995 through 1999
-
Jang MK, Lee JY, Lee JH, Kim YB, Kim HY, Lee MS, Park CK, Yoo JY
- KMID: 759553
- Korean J Intern Med.
- 2001 Sep;16(3):153-159.
BACKGROUND: We analyzed serologic data that were obtained from the Korea Association of Health from 1995 to 1999 to estimate the reliable prevalence of HBV in South Korea. METHODS: 603,375,... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors and Clinical Outcome of Viral Breakthrough during Lamivudine Treatment for Chronic Hepatitis B Infection
-
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH
- KMID: 1085302
- Korean J Hepatol.
- 2003 Dec;9(4):293-303.
BACKGROUND/AIMS: Long-term treatment with lamivudine causes breakthrough, but the clinical course after lamivudine breakthrough is not well known. The aims of this study were to evaluate the clinical course... -
- CITED
-
- Close
- SHARE
-
- Close
- HBV DNA Loss within 24 Weeks Predicts Late Viral Breakthrough in Chronic Hepatitis B
-
Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS
- KMID: 1792811
- Korean J Gastroenterol.
- 2011 Jul;58(1):25-30.
- doi: 10.4166/kjg.2011.58.1.25
BACKGROUND/AIMS: Sustained HBV DNA reduction is necessary for biochemical remission, histological improvement, and prevention of complications. We analyzed the time taken from HBV DNA loss to viral breakthrough after antiviral... -
- CITED
-
- Close
- SHARE
-
- Close
